Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1055/s-0040-1713152 http://scihub22266oqcxt.onion/10.1055/s-0040-1713152 32473596!7516364!32473596     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32473596&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Thromb+Haemost 2020 ; 120 (7): 1004-1024 Nephropedia Template TP {{tp|p=32473596|t=2020. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research |pdf=|usr=}}{{32473596}} gab.com Text Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research JO: Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32473596 #FOAvip Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19. Twit Text FOAVip Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research ????Thromb Haemost http://www.kidney.de/pget.php?&tw=1&pmid=32473596 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32473596 #FOAvip English Wikipedia <ref>{{Cite pmid|32473596}}</ref> Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research #MMPMID32473596 Bikdeli B; Madhavan MV; Gupta A; Jimenez D; Burton JR; Der Nigoghossian C; Chuich T; Nouri SN; Dreyfus I; Driggin E; Sethi S; Sehgal K; Chatterjee S; Ageno W; Madjid M; Guo Y; Tang LV; Hu Y; Bertoletti L; Giri J; Cushman M; Quere I; Dimakakos EP; Gibson CM; Lippi G; Favaloro EJ; Fareed J; Tafur AJ; Francese DP; Batra J; Falanga A; Clerkin KJ; Uriel N; Kirtane A; McLintock C; Hunt BJ; Spyropoulos AC; Barnes GD; Eikelboom JW; Weinberg I; Schulman S; Carrier M; Piazza G; Beckman JA; Leon MB; Stone GW; Rosenkranz S; Goldhaber SZ; Parikh SA; Monreal M; Krumholz HM; Konstantinides SV; Weitz JI; Lip GYH Thromb Haemost 2020[Jul]; 120 (7): 1004-1024 PMID32473596show ga Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19. |Animals[MESH] |Anti-Inflammatory Agents/therapeutic use[MESH] |Anticoagulants/therapeutic use[MESH] |Antiviral Agents/therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/complications/drug therapy/*immunology[MESH] |Fibrinolytic Agents/*therapeutic use[MESH] |Glycosaminoglycans/therapeutic use[MESH] |Hemostasis[MESH] |Humans[MESH] |Inflammation/complications/*drug therapy/immunology[MESH] |Pandemics[MESH] |Platelet Aggregation Inhibitors/therapeutic use[MESH] |Pneumonia, Viral/complications/drug therapy/*immunology[MESH] |SARS-CoV-2[MESH]Pharmacological Agents Targeting Thromboinflammation in COVID-19: Revi(epmc).pdf DeepDyve Pubget Overpricing